Unfortunately, in many cases, the biochemical approach to disease, at best can manage symptoms, and as a result, many conditions remain "incurable" while non-patentable natural therapies that can cure them languish in obscurity.

That's why, despite spending an ever increasing amount of money on Alzheimer's research (e.g., the NIH spent 2.9 billion in 2020 and 3.9 billion in 2024), we've still failed to make any real progress on the disease. This is particularly remarkable given the vast costs to the country (e.g., last year Alzheimer's was estimated to cost the United States 360 billion dollars) and the even greater social costs that accompany it.

The Amyloid Juggernaut

In 1906, plaques (of amyloid) in the brain were identified as the cause of Alzheimer's disease. As the years have gone by, the majority of research for treating Alzheimer's disease has been targeted at eliminating these plaques. Unfortunately, to quote a 2022 article:

Hundreds of clinical trials of amyloid-targeted therapies have yielded few glimmers of promise, however; only the underwhelming Aduhelm has gained FDA approval. Yet Aβ still dominates research and drug development. NIH spent about $1.6 billion on projects that mention amyloids in this fiscal year, about half its overall Alzheimer's funding. Scientists who advance other potential Alzheimer's causes, such as immune dysfunction or inflammation, complain they have been sidelined by the "amyloid mafia." Forsayeth says the amyloid hypothesis became "the scientific equivalent of the Ptolemaic model of the Solar System," in which the Sun and planets rotate around Earth.

Note: frequently, when a faulty paradigm fails to explain the disease it claims to address, rather than admit the paradigm is flawed, its adherents will label each conflicting piece of evidence as a paradox (e.g., the French "paradox" disproves the notion cholesterol causes heart disease4) and dig deeper and deeper until they can find something to continue propping up their ideology (e.g., cholesterol reducing statins provide almost no benefit for heart disease while having significant side effects yet continue being pushed on patients).

The consistent failure of the amyloid model to cure Alzheimer's gradually invited increasing skepticism towards it, which resulted in more and more scientists studying alternative models of the disease. Before long, they found other factors played a far more significant role in causing the disease (e.g., chronic inflammation), and by 2006, this perspective appeared poised to change the direction of Alzheimer's research.